Literature DB >> 19925876

Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.

Patrick Wuchter1, Dan Ran, Thomas Bruckner, Thomas Schmitt, Mathias Witzens-Harig, Kai Neben, Hartmut Goldschmidt, Anthony D Ho.   

Abstract

As more efficient agents for stem cell mobilization are being developed, there is an urgent need to define which patient population might benefit from these novel drugs. For a precise and prospective definition of "poor mobilization" (PM), we have analyzed the efficiency of mobilization in patients intended to receive autologous transplantation at our center in the past 6 years. Between January 2003, and December 2008, 840 patients with the following diagnoses were scheduled to undergo leukapheresis: multiple myeloma (MM, n = 602) and non-Hodgkin lymphoma (NHL, n= 238). Most patients mobilized readily: close to 85% of the patients had a level of 20/microL to >500/microL of CD34(+) cells at the peak of stimulation. Of the 840 patients, 129 (15.3%) were considered to be PMs, defined as patients who had a peak concentration of <20/microL of CD34(+) cells upon stimulation with granulocyte-colony stimulating factor (G-CSF) subsequent to induction chemotherapy appropriate for the respective disease. Among them, 38 (4.5%) patients had CD34(+) levels between 11 and 19/microL at maximum stimulation, defined as "borderline" PM, 49 (5.8%) patients had CD34(+) levels between 6 and 10/microL, defined as "relative" PM, and 42 patients (5%) with levels of <5/microL, defined as "absolute" PM. There was no difference in the incidence of PM between patients with MM versus those with NHL. Sex, age, body weight (b.w.) and previous irradiation therapy did not make any significant difference. Only the total number of cycles of previous chemotherapy (P = .0034), and previous treatment with melphalan (Mel; P = .0078) had a significant impact on the ability to mobilize. For the good mobilizers, the median time to recovery of the white blood cells (WBCs) to 1.0/nL or more was 13 days with a range of 7 to 22 days, whereas for the PM group it was 14 days with a range of 8 to 37 days. This difference was statistically not significant. The median time to recovery of the platelets counts to an unmaintained level of >20/nL was 11 days with a range of 6 to 17 days for the good mobilizers, whereas for the PM it was 11 days with a range of 7 to 32 days. Again, this difference was not significant. The majority of the patients today intended for autologous transplantations were able to mobilize readily. As long as > or =2.0 x 10(6) of CD34(+) cells/kg b.w. have been collected, PM was not associated with inferior engraftment. Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19925876     DOI: 10.1016/j.bbmt.2009.11.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  46 in total

1.  Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.

Authors:  Santosh Saraf; Hiroto Araki; Benjamin Petro; Youngmin Park; Simona Taioli; Kazumi G Yoshinaga; Emre Koca; Damiano Rondelli; Nadim Mahmud
Journal:  Transfusion       Date:  2014-11-02       Impact factor: 3.157

2.  Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.

Authors:  Lauren Veltri; Aaron Cumpston; Alexandra Shillingburg; Sijin Wen; Jin Luo; Sonia Leadmon; Kathy Watkins; Michael Craig; Mehdi Hamadani; Abraham S Kanate
Journal:  Cytotherapy       Date:  2015-10-21       Impact factor: 5.414

3.  Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.

Authors:  S Afifi; N G Adel; S Devlin; E Duck; J Vanak; H Landau; D J Chung; N Lendvai; A Lesokhin; N Korde; L Reich; O Landgren; S Giralt; H Hassoun
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 4.  Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Authors:  M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte
Journal:  Bone Marrow Transplant       Date:  2014-03-31       Impact factor: 5.483

5.  Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.

Authors:  Andreas Humpe; Ute Buwitt-Beckmann; Natalie Schub; Martin Gramatzki; Andreas Günther
Journal:  Transfus Med Hemother       Date:  2013-07-25       Impact factor: 3.747

6.  Norepinephrine reuptake inhibition promotes mobilization in mice: potential impact to rescue low stem cell yields.

Authors:  Daniel Lucas; Ingmar Bruns; Michela Battista; Simon Mendez-Ferrer; Claire Magnon; Yuya Kunisaki; Paul S Frenette
Journal:  Blood       Date:  2012-03-14       Impact factor: 22.113

7.  Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.

Authors:  Giuseppe Milone; Giovanni Tripepi; Massimo Martino; Flavia Ancora; Benedetta Bartolozzi; Andrea Spadaro; Chiara Nozzoli; Alessia La Fauci; Irene Amico; Salvatore Leotta; Massimo Poidomani; Giuseppe Irrera; Pasquale Iacopino; Riccardo Saccardi; Stefano Guidi; Alberto Bosi
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

8.  Collection and Processing of Mobilized Mouse Peripheral Blood at Lowered Oxygen Tension Yields Enhanced Numbers of Hematopoietic Stem Cells.

Authors:  Arafat Aljoufi; Scott Cooper; Hal E Broxmeyer
Journal:  Stem Cell Rev Rep       Date:  2020-10       Impact factor: 5.739

9.  Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Authors:  Nigel Russell; Kenny Douglas; Anthony D Ho; Mohamad Mohty; Kristina Carlson; G J Ossenkoppele; Giuseppe Milone; Macarena Ortiz Pareja; Daniel Shaheen; Arnold Willemsen; Nicky Whitaker; Christian Chabannon
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

10.  Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting.

Authors:  Rajiv Kumar; Rajan Kapoor; Bhushan Asthana; Jasjit Singh; Tarun Verma; Rajesh Chilaka; N K Singh; Ajay Sharma; S Das; Velu Nair
Journal:  Indian J Hematol Blood Transfus       Date:  2017-03-03       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.